HCMV Antivirals and Strategies to Target the Latent Reservoir.
MetadataShow full item record
Perera, M. R., Wills, M., & Sinclair, J. (2021). HCMV Antivirals and Strategies to Target the Latent Reservoir.. Viruses, 13 (5)https://doi.org/10.3390/v13050817
Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. In healthy people, primary infection is generally asymptomatic, and the virus can go on to establish lifelong latency in cells of the myeloid lineage. However, HCMV often causes severe disease in the immunosuppressed: transplant recipients and people living with AIDS, and also in the immunonaive foetus. At present, there are several antiviral drugs licensed to control HCMV disease. However, these are all faced with problems of poor bioavailability, toxicity and rapidly emerging viral resistance. Furthermore, none of them are capable of fully clearing the virus from the host, as they do not target latent infection. Consequently, reactivation from latency is a significant source of disease, and there remains an unmet need for treatments that also target latent infection. This review briefly summarises the most common HCMV antivirals used in clinic at present and discusses current research into targeting the latent HCMV reservoir.
Humans, Cytomegalovirus, Cytomegalovirus Infections, Disease Susceptibility, Antiviral Agents, Organ Transplantation, Disease Reservoirs, Virus Latency, Virus Activation, Drug Development
This research was funded by the Medical Research Council (MRC) Programme Grant (grant number MR/S00081X/1) and an MRC Doctoral Training grant to M.R.P. (grant number RG86932).
External DOI: https://doi.org/10.3390/v13050817
This record's URL: https://www.repository.cam.ac.uk/handle/1810/322002
All rights reserved